Rein Therapeutics, Inc. Common Stock RNTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on assets | -119.7%-4.2pp | -115.5%-40.9pp | -74.6%-3.7pp | -70.9%+7.3pp | -78.1%-3.4pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 0.4×-0.3× | 0.7×-0.2× | 0.9×0.0× | 0.9×-0.5× | 1.4×-1.0× | |
| Quick ratio | 0.4×-0.3× | 0.7×-0.2× | 0.9×0.0× | 0.9×-0.5× | 1.4×-1.0× | |
| Cash ratio | 0.3×-0.2× | 0.5×-0.2× | 0.7×0.0× | 0.7×-0.5× | 1.2×-1.0× | |
| Valuation | ||||||
| Market capitalization | $88.96M+164% | $30.49M+10.8% | $27.51M-15.5% | $32.57M— | —— | |
| Earnings yield | -59.2%+125pp | -163.6%+50.5pp | -214%-32.4pp | -181.6%— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Rein Therapeutics, Inc. Common Stock's ratios come from?
- Every ratio is computed from Rein Therapeutics, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.